Global Rapid Influenza Diagnostic Tests Market Size By Type (Influenza A, Influenza B), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global Rapid Influenza Diagnostic Tests (RIDTs) Market was valued at USD 1.1 billion in 2023 and is projected to surpass USD 2.1 billion by 2031, expanding at a CAGR of 8.2% during the forecast period of 2023–2031. This growth is driven by increasing global incidence of influenza, rising public health awareness, advancements in point-of-care (POC) testing technologies, and the urgent need for timely diagnosis to initiate appropriate treatment and reduce disease transmission. The ongoing integration of RIDTs into public health surveillance systems and the surge in demand for decentralized testing post-COVID-19 are bolstering market expansion.

Drivers:

1. Growing Incidence of Seasonal and Pandemic Influenza:

The global burden of influenza, including emerging pandemic strains, has emphasized the need for early and accurate diagnosis. RIDTs offer a quick turnaround time, enabling healthcare providers to manage and contain outbreaks effectively.

2. Technological Advancements in Diagnostic Devices:

Newer RIDTs have improved sensitivity and specificity, along with user-friendly features and digital integration. Innovations in multiplex testing—detecting multiple pathogens in a single assay—are also contributing to market growth.

3. Expanding Point-of-Care Testing:

Decentralized testing, including home-based and pharmacy-based diagnostics, is gaining momentum. RIDTs fit seamlessly into this trend due to their rapid results and minimal infrastructure needs.

Restraints:

1. Variability in Test Accuracy:

Despite technological advancements, some RIDTs still face limitations in sensitivity, especially in asymptomatic or early-stage infections. This can result in false negatives and compromise disease management.

2. Regulatory and Reimbursement Challenges:

Stringent approval processes and lack of consistent reimbursement policies across regions hinder the market penetration of newer diagnostic products, especially in developing countries.

Opportunity:

1. Integration with Digital Health Platforms:

The incorporation of RIDTs with mobile apps and cloud-based health tracking platforms presents a significant opportunity. These integrations can facilitate real-time disease surveillance and personalized care.

2. Rising Demand in Emerging Markets:

Improving healthcare infrastructure, increased healthcare funding, and greater awareness in Asia-Pacific, Latin America, and parts of Africa are unlocking new growth avenues for RIDT providers.

Market by System Type Insights:

The Digital Immunoassay-Based RIDTs segment dominated the market in 2023 due to their enhanced analytical performance and automated result interpretation. These tests offer greater reliability and are increasingly adopted in clinical settings and by public health authorities. Traditional visually read RIDTs still hold substantial market share, especially in resource-limited settings due to their low cost and ease of use.

Market by End-Use Insights:

Hospitals and Diagnostic Laboratories held the largest market share in 2023, benefiting from bulk procurement, skilled personnel, and access to advanced testing infrastructure. The Retail Clinics and Pharmacies segment is expected to witness the fastest growth during the forecast period, driven by the rising trend of over-the-counter diagnostics and patient preference for convenience.

Market by Regional Insights:

North America led the global market in 2023, attributed to well-established healthcare infrastructure, strong presence of key players, and high public awareness. However, Asia-Pacific is expected to witness the highest CAGR through 2031, propelled by expanding healthcare access, rising infectious disease prevalence, and increased investments in diagnostic innovation.

Competitive Scenario:

Prominent players in the Global Rapid Influenza Diagnostic Tests Market include Abbott Laboratories, F. Hoffmann-La Roche Ltd, QuidelOrtho Corporation, Becton, Dickinson and Company, Thermo Fisher Scientific, Danaher Corporation, bioMérieux SA, Sekisui Diagnostics, Meridian Bioscience, and Siemens Healthineers. These companies are focusing on R&D, strategic partnerships, and geographic expansion.

Key Developments:

In 2024, QuidelOrtho launched a next-generation multiplex test capable of detecting influenza A/B, RSV, and COVID-19 with high sensitivity.

Abbott Laboratories expanded its manufacturing capabilities in 2023 to meet growing global demand for POC diagnostic tests.

In 2022, Roche Diagnostics integrated its RIDTs into a real-time health monitoring platform for improved outbreak management.

Scope of Work – Global Rapid Influenza Diagnostic Tests Market

Report Metric Details

Market Size (2023) USD 1.1 billion

Projected Market Size (2031) USD 2.1 billion

CAGR (2023–2031) 8.2%

Key Segments By System Type (Digital Immunoassay, Traditional Visual), By End-use

Growth Drivers Rising influenza cases, technological advances, demand for POC diagnostics

Opportunities Digital health integration, emerging market adoption

FAQs:

1) What is the current market size of the Global Rapid Influenza Diagnostic Tests Market?

The market was valued at USD 1.1 billion in 2023.

2) What is the major growth driver of the Global Rapid Influenza Diagnostic Tests Market?

Rising global incidence of influenza and increased adoption of point-of-care diagnostics are major growth drivers.

3) Which is the largest region during the forecast period in the Global Rapid Influenza Diagnostic Tests Market?

North America is the largest region, while Asia-Pacific is expected to grow the fastest.

4) Which segment accounted for the largest market share in the Global Rapid Influenza Diagnostic Tests Market?

The Digital Immunoassay-Based RIDTs segment accounted for the largest share in 2023.

5) Who are the key market players in the Global Rapid Influenza Diagnostic Tests Market?

Key players include Abbott Laboratories, Roche, QuidelOrtho, BD, Thermo Fisher Scientific, and Siemens Healthineers.